Anaphylaxis: Difference between revisions

(Major update: epinephrine IM dosing/frequency, biphasic reaction monitoring, diagnostic criteria, glucagon for beta-blocker patients, methylene blue, EpiPen prescription, discharge plan, references with PMIDs)
(Strip excess bold text - keep only critical safety emphasis)
 
Line 3: Line 3:
*IgE-mediated (type I hypersensitivity) in most cases; can also be non-IgE mediated (anaphylactoid)
*IgE-mediated (type I hypersensitivity) in most cases; can also be non-IgE mediated (anaphylactoid)
*'''Biphasic reaction''' occurs in '''5-20%''' of cases (recurrence 1-72 hours after initial reaction, usually within 8-10 hours)<ref>Lee S, et al. Biphasic anaphylaxis: review of incidence, clinical predictors, and observation recommendations. ''Immunol Allergy Clin North Am''. 2015;35(2):313-326. PMID 25841553</ref>
*'''Biphasic reaction''' occurs in '''5-20%''' of cases (recurrence 1-72 hours after initial reaction, usually within 8-10 hours)<ref>Lee S, et al. Biphasic anaphylaxis: review of incidence, clinical predictors, and observation recommendations. ''Immunol Allergy Clin North Am''. 2015;35(2):313-326. PMID 25841553</ref>
*'''Epinephrine is the ONLY first-line treatment''' — delays in administration increase mortality
*Epinephrine is the ONLY first-line treatment — delays in administration increase mortality


===Common Triggers===
===Common Triggers===
*'''Foods''' (most common overall): peanuts, tree nuts, shellfish, fish, milk, eggs, wheat, soy
*Foods (most common overall): peanuts, tree nuts, shellfish, fish, milk, eggs, wheat, soy
*'''Medications''': antibiotics (penicillin, cephalosporins), NSAIDs, neuromuscular blocking agents
*Medications: antibiotics (penicillin, cephalosporins), NSAIDs, neuromuscular blocking agents
*'''Insect stings''': Hymenoptera (bees, wasps, hornets, fire ants)
*Insect stings: Hymenoptera (bees, wasps, hornets, fire ants)
*'''Latex'''
*Latex
*'''Exercise-induced anaphylaxis''' (sometimes food-dependent)
*'''Exercise-induced anaphylaxis''' (sometimes food-dependent)
*'''Idiopathic''' (~20% — no identifiable trigger)
*Idiopathic (~20% — no identifiable trigger)


==Clinical Features==
==Clinical Features==
*Onset: '''minutes to hours''' after exposure (usually within 30 minutes)
*Onset: minutes to hours after exposure (usually within 30 minutes)
*'''Skin/mucosal''' (90%): urticaria, flushing, angioedema, pruritus
*Skin/mucosal (90%): urticaria, flushing, angioedema, pruritus
*'''Respiratory''' (70%): '''laryngeal edema''', stridor, bronchospasm, wheezing, dyspnea
*Respiratory (70%): laryngeal edema, stridor, bronchospasm, wheezing, dyspnea
*'''Cardiovascular''' (45%): [[hypotension]], [[tachycardia]], distributive [[shock]], syncope, '''cardiac arrest'''
*Cardiovascular (45%): [[hypotension]], [[tachycardia]], distributive [[shock]], syncope, cardiac arrest
*'''GI''' (45%): nausea, vomiting, abdominal cramps, diarrhea
*GI (45%): nausea, vomiting, abdominal cramps, diarrhea
*'''Neurologic''': anxiety, dizziness, altered mental status
*'''Neurologic''': anxiety, dizziness, altered mental status
*'''Anaphylaxis can occur WITHOUT skin findings''' (~10-20% of cases)
*'''Anaphylaxis can occur WITHOUT skin findings''' (~10-20% of cases)


===Diagnostic Criteria (Any ONE of Three)===
===Diagnostic Criteria (Any ONE of Three)===
*'''Criterion 1''': Acute onset with skin/mucosal involvement AND respiratory compromise OR hypotension
*Criterion 1: Acute onset with skin/mucosal involvement AND respiratory compromise OR hypotension
*'''Criterion 2''': Two or more systems involved rapidly after likely allergen: skin, respiratory, cardiovascular, GI
*Criterion 2: Two or more systems involved rapidly after likely allergen: skin, respiratory, cardiovascular, GI
*'''Criterion 3''': Hypotension after exposure to known allergen (SBP <90 or >30% decrease from baseline)
*Criterion 3: Hypotension after exposure to known allergen (SBP <90 or >30% decrease from baseline)


==Differential Diagnosis==
==Differential Diagnosis==
Line 38: Line 38:
==Evaluation==
==Evaluation==
*'''Anaphylaxis is a clinical diagnosis''' — do NOT delay treatment for labs
*'''Anaphylaxis is a clinical diagnosis''' — do NOT delay treatment for labs
*'''Serum tryptase''': elevated supports diagnosis (draw within 1-3 hours of onset)
*Serum tryptase: elevated supports diagnosis (draw within 1-3 hours of onset)
**Normal tryptase does NOT exclude anaphylaxis
**Normal tryptase does NOT exclude anaphylaxis
**Useful for postmortem diagnosis and distinguishing from other causes
**Useful for postmortem diagnosis and distinguishing from other causes
Line 46: Line 46:
==Management==
==Management==
===Epinephrine (Cornerstone of Treatment)===
===Epinephrine (Cornerstone of Treatment)===
*'''Epinephrine 0.3-0.5 mg (1:1,000) IM''' in '''anterolateral thigh''' (vastus lateralis)
*Epinephrine 0.3-0.5 mg (1:1,000) IM in anterolateral thigh (vastus lateralis)
**Pediatric: '''0.01 mg/kg (max 0.3 mg)''' IM
**Pediatric: 0.01 mg/kg (max 0.3 mg) IM
**'''Repeat every 5-15 minutes''' as needed
**Repeat every 5-15 minutes as needed
**'''Do NOT delay''' — there are NO absolute contraindications to epinephrine in anaphylaxis
**'''Do NOT delay''' — there are NO absolute contraindications to epinephrine in anaphylaxis
*If refractory or in shock:
*If refractory or in shock:
**'''Epinephrine infusion''': 0.1-0.5 mcg/kg/min IV (mix 1 mg in 250 mL NS = 4 mcg/mL)
**Epinephrine infusion: 0.1-0.5 mcg/kg/min IV (mix 1 mg in 250 mL NS = 4 mcg/mL)
**'''IV epinephrine bolus''' (only for cardiac arrest or refractory shock): 0.1 mg of 1:10,000 IV
**IV epinephrine bolus (only for cardiac arrest or refractory shock): 0.1 mg of 1:10,000 IV
*'''IM > SC''' (faster absorption; SC absorption unreliable in shock)
*IM > SC (faster absorption; SC absorption unreliable in shock)


===Adjunctive Therapies===
===Adjunctive Therapies===
*'''IV fluids''': '''aggressive NS bolus''' (1-2L in adults; 20 mL/kg in children) — distributive shock with massive third-spacing
*IV fluids: aggressive NS bolus (1-2L in adults; 20 mL/kg in children) — distributive shock with massive third-spacing
*'''Albuterol''' 2.5-5 mg nebulized for bronchospasm (does not replace epinephrine)
*Albuterol 2.5-5 mg nebulized for bronchospasm (does not replace epinephrine)
*'''H1 antihistamine''': diphenhydramine 25-50 mg IV (treats urticaria/pruritus; does NOT treat life-threatening features)
*'''H1 antihistamine''': diphenhydramine 25-50 mg IV (treats urticaria/pruritus; does NOT treat life-threatening features)
*'''H2 antihistamine''': famotidine 20 mg IV (adjunctive)
*H2 antihistamine: famotidine 20 mg IV (adjunctive)
*'''Corticosteroids''': methylprednisolone 125 mg IV or prednisone 1 mg/kg PO
*Corticosteroids: methylprednisolone 125 mg IV or prednisone 1 mg/kg PO
**Theoretical benefit in preventing biphasic reaction ('''limited evidence''')
**Theoretical benefit in preventing biphasic reaction (limited evidence)
**'''Do NOT rely on steroids as primary treatment''' (slow onset: 4-6 hours)
**'''Do NOT rely on steroids as primary treatment''' (slow onset: 4-6 hours)
*'''Glucagon''' 1-5 mg IV for patients on '''beta-blockers''' (resistant to epinephrine)
*Glucagon 1-5 mg IV for patients on beta-blockers (resistant to epinephrine)


===Refractory Anaphylaxis===
===Refractory Anaphylaxis===
*Epinephrine infusion + aggressive volume resuscitation
*Epinephrine infusion + aggressive volume resuscitation
*'''Vasopressin''' 1-2 units IV bolus for refractory hypotension
*Vasopressin 1-2 units IV bolus for refractory hypotension
*'''Glucagon''' for beta-blocker use
*Glucagon for beta-blocker use
*Consider '''methylene blue''' 1-2 mg/kg IV for refractory vasoplegia
*Consider methylene blue 1-2 mg/kg IV for refractory vasoplegia
*Secure airway early if airway edema progressing ('''may require surgical airway''')
*Secure airway early if airway edema progressing (may require surgical airway)


==Disposition==
==Disposition==
*'''Observe minimum 4-6 hours''' after last dose of epinephrine (biphasic reaction monitoring)
*Observe minimum 4-6 hours after last dose of epinephrine (biphasic reaction monitoring)
*'''Extended observation (8-24 hours)''' if:
*Extended observation (8-24 hours) if:
**Severe initial reaction (hypotension, intubation)
**Severe initial reaction (hypotension, intubation)
**History of biphasic reactions
**History of biphasic reactions
**Delayed presentation
**Delayed presentation
**Poor access to medical care
**Poor access to medical care
*'''Discharge with''':
*Discharge with:
**'''Epinephrine auto-injector prescription''' (EpiPen or equivalent) — prescribe '''2 devices'''
**Epinephrine auto-injector prescription (EpiPen or equivalent) — prescribe 2 devices
**Antihistamine (diphenhydramine or cetirizine) for 3 days
**Antihistamine (diphenhydramine or cetirizine) for 3 days
**Prednisone 40-60 mg PO daily × 3-5 days
**Prednisone 40-60 mg PO daily × 3-5 days
**'''Allergist referral'''
**Allergist referral
**'''Written anaphylaxis action plan'''
**'''Written anaphylaxis action plan'''
**'''Strict avoidance of trigger'''
**Strict avoidance of trigger
**'''Return precautions''': return immediately if symptoms recur
**'''Return precautions''': return immediately if symptoms recur



Latest revision as of 09:23, 22 March 2026

Background

  • Acute, life-threatening, systemic allergic reaction involving multiple organ systems
  • IgE-mediated (type I hypersensitivity) in most cases; can also be non-IgE mediated (anaphylactoid)
  • Biphasic reaction occurs in 5-20% of cases (recurrence 1-72 hours after initial reaction, usually within 8-10 hours)[1]
  • Epinephrine is the ONLY first-line treatment — delays in administration increase mortality

Common Triggers

  • Foods (most common overall): peanuts, tree nuts, shellfish, fish, milk, eggs, wheat, soy
  • Medications: antibiotics (penicillin, cephalosporins), NSAIDs, neuromuscular blocking agents
  • Insect stings: Hymenoptera (bees, wasps, hornets, fire ants)
  • Latex
  • Exercise-induced anaphylaxis (sometimes food-dependent)
  • Idiopathic (~20% — no identifiable trigger)

Clinical Features

  • Onset: minutes to hours after exposure (usually within 30 minutes)
  • Skin/mucosal (90%): urticaria, flushing, angioedema, pruritus
  • Respiratory (70%): laryngeal edema, stridor, bronchospasm, wheezing, dyspnea
  • Cardiovascular (45%): hypotension, tachycardia, distributive shock, syncope, cardiac arrest
  • GI (45%): nausea, vomiting, abdominal cramps, diarrhea
  • Neurologic: anxiety, dizziness, altered mental status
  • Anaphylaxis can occur WITHOUT skin findings (~10-20% of cases)

Diagnostic Criteria (Any ONE of Three)

  • Criterion 1: Acute onset with skin/mucosal involvement AND respiratory compromise OR hypotension
  • Criterion 2: Two or more systems involved rapidly after likely allergen: skin, respiratory, cardiovascular, GI
  • Criterion 3: Hypotension after exposure to known allergen (SBP <90 or >30% decrease from baseline)

Differential Diagnosis

  • Angioedema (hereditary or ACE-inhibitor — no urticaria)
  • Vasovagal syncope (bradycardia; no urticaria/wheezing)
  • Asthma exacerbation
  • Urticaria alone (without systemic involvement)
  • Carcinoid syndrome, mastocytosis, scombroid fish poisoning
  • Anxiety / panic attack
  • Vocal cord dysfunction

Evaluation

  • Anaphylaxis is a clinical diagnosis — do NOT delay treatment for labs
  • Serum tryptase: elevated supports diagnosis (draw within 1-3 hours of onset)
    • Normal tryptase does NOT exclude anaphylaxis
    • Useful for postmortem diagnosis and distinguishing from other causes
  • Monitor: continuous ECG, pulse oximetry, blood pressure
  • Consider: CBC, BMP, troponin (Kounis syndrome — allergic MI)

Management

Epinephrine (Cornerstone of Treatment)

  • Epinephrine 0.3-0.5 mg (1:1,000) IM in anterolateral thigh (vastus lateralis)
    • Pediatric: 0.01 mg/kg (max 0.3 mg) IM
    • Repeat every 5-15 minutes as needed
    • Do NOT delay — there are NO absolute contraindications to epinephrine in anaphylaxis
  • If refractory or in shock:
    • Epinephrine infusion: 0.1-0.5 mcg/kg/min IV (mix 1 mg in 250 mL NS = 4 mcg/mL)
    • IV epinephrine bolus (only for cardiac arrest or refractory shock): 0.1 mg of 1:10,000 IV
  • IM > SC (faster absorption; SC absorption unreliable in shock)

Adjunctive Therapies

  • IV fluids: aggressive NS bolus (1-2L in adults; 20 mL/kg in children) — distributive shock with massive third-spacing
  • Albuterol 2.5-5 mg nebulized for bronchospasm (does not replace epinephrine)
  • H1 antihistamine: diphenhydramine 25-50 mg IV (treats urticaria/pruritus; does NOT treat life-threatening features)
  • H2 antihistamine: famotidine 20 mg IV (adjunctive)
  • Corticosteroids: methylprednisolone 125 mg IV or prednisone 1 mg/kg PO
    • Theoretical benefit in preventing biphasic reaction (limited evidence)
    • Do NOT rely on steroids as primary treatment (slow onset: 4-6 hours)
  • Glucagon 1-5 mg IV for patients on beta-blockers (resistant to epinephrine)

Refractory Anaphylaxis

  • Epinephrine infusion + aggressive volume resuscitation
  • Vasopressin 1-2 units IV bolus for refractory hypotension
  • Glucagon for beta-blocker use
  • Consider methylene blue 1-2 mg/kg IV for refractory vasoplegia
  • Secure airway early if airway edema progressing (may require surgical airway)

Disposition

  • Observe minimum 4-6 hours after last dose of epinephrine (biphasic reaction monitoring)
  • Extended observation (8-24 hours) if:
    • Severe initial reaction (hypotension, intubation)
    • History of biphasic reactions
    • Delayed presentation
    • Poor access to medical care
  • Discharge with:
    • Epinephrine auto-injector prescription (EpiPen or equivalent) — prescribe 2 devices
    • Antihistamine (diphenhydramine or cetirizine) for 3 days
    • Prednisone 40-60 mg PO daily × 3-5 days
    • Allergist referral
    • Written anaphylaxis action plan
    • Strict avoidance of trigger
    • Return precautions: return immediately if symptoms recur

See Also

References

  1. Lee S, et al. Biphasic anaphylaxis: review of incidence, clinical predictors, and observation recommendations. Immunol Allergy Clin North Am. 2015;35(2):313-326. PMID 25841553
  • Lieberman P, et al. Anaphylaxis — a practice parameter update 2015. Ann Allergy Asthma Immunol. 2015;115(5):341-384. PMID 26505932
  • Cardona V, et al. World Allergy Organization anaphylaxis guidance 2020. World Allergy Organ J. 2020;13(10):100472. PMID 33204386
  • Simons FER, et al. World Allergy Organization guidelines for the assessment and management of anaphylaxis. World Allergy Organ J. 2011;4(2):13-37. PMID 23268454
  • Shaker MS, et al. Anaphylaxis — a 2020 practice parameter update. J Allergy Clin Immunol. 2020;145(4):1082-1123. PMID 32001253